


Nouveaux traitements en cardiologie

Dr Vincent Algalarrondo

CCMR amyloses cardiaques - CHU Bichat




Liens d'intérêts

- Alnylam
- Pfizer
- Astrazeneca
- Abbott
- Microport

Plan

- Thérapies de support
- Thérapies spécifique anti amylose
 - > Etude Patisiran: Apollo B study
 - > Anticorps
 - > Pipeline des études en cours

Thérapie de support



- Tt de l'IC et amylose
- Vers une approche pragmatique
 - MRA possibles
 - BB possibles (FA++)
 - Surveillance +++
 - Objectif tt (TA, FC)

LVEF ≤40%

No effect


LVEF >40%

Thérapies spécifiques anti amylose : Patisiran

APPOLLO B: patisiran

360 patients

334 patients




Characteristic	Patisiran (N=181)	Placebo (N=178)
Age, median (range), years	76 (47–85)	76 (41–85)
Male sex, n (%)	161 (89.0)	160 (89.9)
Race, n (%)		
White	138 (76)	140 (79)
Asian	23 (13)	15 (8)
Black or African American	16 (9)	15 (8)
ATTRwt amyloidosis, n (%)	144 (80)	144 (81)
Time since diagnosis of ATTR amyloidosis, median (range), years	0.8 (0–6)	0.4 (0–10)
Baseline tafamidis use, n (%)	46 (25)	45 (25)
NYHA class, n (%)		
Class I	10 (6)	15 (8)
Class II	156 (86)	150 (84)
Class III	15 (8)	13 (7)

Thérapies spécifiques anti amylose : Patisiran

Primary endpoint:


Mean Change from Baseline in 6-MWT



No. of patients					
Placebo	178	165	165	164	146
Patisiran	181	162	167	167	149

Secondary endpoint:


Mean Change from Baseline in KCCQ-OS



No. of patients					
Placebo	178	171	168	167	155
Patisiran	181	170	171	171	157

■ Patisiran ■ Placebo

Thérapies spécifiques anti amylose : Patisiran



Thérapies spécifiques : dépleteur NI006



- Anticorps humain anti ATTR
- Etude de phase I : 40 patients
 - Rando 2:1
 - Une iv chaque mois pendant 4 mois
- Résultats
 - Tolérance OK
 - Tendances : NT pro BNP, DPD

=> phase III


Aubin Michalon, Nat com 2021

Pablo Garcia-Pavia et al, NEJM 2023, NEJM 2023, published online on May 20

Cardiac Tracer Uptake on Scintigraphy



Pipeline: phase III en cours / en démarrage



Pipeline: phase III en cours

Etude	Produit	N	Critère	Résultats
HELIOS B	Vutrisiran	655	Mortalité tot + hospit CV	Fin 2024
CARDIOTTRANSFOM	Eplontersen	1400	Mortalité CV et evenement CV	2024?
ATTRibute-CM	Acoramidis	632	Mortalité tot + hospit CV (hiérarchie)	2025

Crispr Cas9, Ac anti ATTR: phase III (x2?) non initiées

Conclusion

- Nouveautés positives
 - Patisiran en cardio?
- Grosses études en cours / attente
 - 3 phases III en cours
 - 2(-3?) phases III en préparation



Merci pour votre attention!!